Fig. 3
From: A polo-like kinase inhibitor identified by computational repositioning attenuates pulmonary fibrosis
PLK1 expression in myofibroblasts and PLK2 expression in lung epithelial cells. C57BL/6 mice received bleomycin (3 mg/kg, intratracheal instillation) on day 0. The lung tissue was harvested on day 21. (A-B) Paraffin-embedded lung sections were stained with an anti-PLK1 antibody (green) and anti-α-SMA antibody (red) or with an anti-pro-SPC antibody (green) and anti-PLK2 antibody (red). Representative images of immunofluorescence staining in control group or bleomycin-treated group are shown. Yellow arrows indicate cells double-positive for PLK1 and α-SMA (A), for PLK2 and pro-SPC (B). Scale bars, 100 mm